HHS Secretary Robert F. Kennedy Jr. remains entrenched over a year into his tenure, driving trader consensus to 76.5% odds against his exit by December 31, 2026, amid administration efforts to stabilize his role ahead of November midterms. Recent developments include a February leadership shakeup where Deputy Secretary Jim O'Neill and General Counsel Mike Stuart departed, but Kennedy announced restructuring to advance priorities, signaling continuity. Criticism intensified last week over measles outbreaks and vitamin A toxicity cases linked to parental advice echoing his views, alongside a federal judge partially blocking his vaccine agenda; however, White House messaging restrictions position him on safer topics. No resignation signals or Senate pressures have emerged, with his April 16 House committee testimony looming as a potential flashpoint.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedAn announcement of Robert F. Kennedy Jr. (RFK Jr.)'s resignation/removal before this market's end date will immediately resolve this market to "Yes", regardless of when the announced resignation/removal goes into effect.
The resolution source for this market will be official information from Robert F. Kennedy Jr. (RFK Jr.) and the U.S. government; however, a consensus of credible reporting may also be used.
Market Opened: Mar 19, 2026, 2:02 PM ET
Resolver
0x65070BE91...An announcement of Robert F. Kennedy Jr. (RFK Jr.)'s resignation/removal before this market's end date will immediately resolve this market to "Yes", regardless of when the announced resignation/removal goes into effect.
The resolution source for this market will be official information from Robert F. Kennedy Jr. (RFK Jr.) and the U.S. government; however, a consensus of credible reporting may also be used.
Resolver
0x65070BE91...HHS Secretary Robert F. Kennedy Jr. remains entrenched over a year into his tenure, driving trader consensus to 76.5% odds against his exit by December 31, 2026, amid administration efforts to stabilize his role ahead of November midterms. Recent developments include a February leadership shakeup where Deputy Secretary Jim O'Neill and General Counsel Mike Stuart departed, but Kennedy announced restructuring to advance priorities, signaling continuity. Criticism intensified last week over measles outbreaks and vitamin A toxicity cases linked to parental advice echoing his views, alongside a federal judge partially blocking his vaccine agenda; however, White House messaging restrictions position him on safer topics. No resignation signals or Senate pressures have emerged, with his April 16 House committee testimony looming as a potential flashpoint.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions